The Safety and Efficacy of Basiliximab as Maintenance Therapy in Subjects With Stable, Noninfectious Uveitis

Phase 2 Terminated 5 enrolled Cerimon Pharmaceuticals PPD Development, LP · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of this trial is to assess if treatment with basiliximab allows subjects to taper off other immunosuppressive drug regimens without causing an increase in their uveitis.

Timeline

Start: 2008-05
Primary completion: 2008-11
Completion: 2008-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Basiliximab	Monoclonal antibody	40 mg	Intravenous

The Safety and Efficacy of Basiliximab as Maintenance Therapy in Subjects With Stable, Noninfectious Uveitis

Summary

Timeline

Drugs

Indications